Ocular Adverse Events After Influenza Vaccination in Older Adults: Self-Controlled Case Series Using a Large Database in Japan

被引:0
作者
Hashimoto, Yohei [1 ,2 ,3 ,11 ]
Iwagami, Masao [4 ]
Yamana, Hayato [5 ]
Ono, Sachiko [6 ]
Takeuchi, Yoshinori [7 ,8 ]
Michihata, Nobuaki [9 ]
Uemura, Kohei [10 ]
Aihara, Makoto [1 ]
Yasunaga, Hideo [2 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan
[2] Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Tokyo, Japan
[3] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia
[4] Univ Tsukuba, Fac Med, Dept Hlth Serv Res, Ibaraki, Japan
[5] Jichi Med Univ, Data Sci Ctr, Shimotsuke, Tochigi, Japan
[6] Univ Tokyo, Grad Sch Med, Dept Eat Loss Med, Tokyo, Japan
[7] Toho Univ, Fac Med, Dept Social Med, Div Med Stat, Tokyo, Japan
[8] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan
[9] Chiba Canc Ctr Res Inst, Canc Prevent Ctr, Chiba, Japan
[10] Univ Tokyo, Dept Biostat & Bioinformat, Interfac Initiat Informat Studies, Tokyo, Japan
[11] Univ Sydney, Sydney Hosp, Save Sight Inst, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia
关键词
Influenza; ocular adverse events; older adults; self-controlled case series; vaccination; OPTIC NEURITIS; SEASONAL INFLUENZA; UNITED-STATES;
D O I
10.1080/09286586.2023.2289990
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
BackgroundTo clarify the risk of adverse ocular events following influenza vaccination.MethodsThis self-controlled case series study used a claims database linked to vaccination records of a large city in Japan between April 2014 and September 2021. Individuals aged >= 65 years who developed adverse ocular events during the follow-up period were included. The exposure was influenza vaccination. The primary outcome was defined as the occurrence of at least one of the following five eye diseases: uveitis, scleritis, retinal vein occlusion, retinal artery occlusion, or optic neuritis. Conditional Poisson regression was used to estimate the within-subject incidence rate ratio of ocular adverse events during the risk period (0-56 days after vaccination) compared to the control period.ResultsA total of 4,527 cases were eligible for the study (median age, 74 years; male, 42%). The incidence rate ratio for the outcome during the risk period was 0.99 (95% confidence interval, 0.87 to 1.14). No increased risk was observed for individual components of the outcome either; the incidence rate ratio was 0.94 (0.78 to 1.13) for uveitis, 1.17 (0.86 to 1.59) for scleritis, 0.98 (0.76 to 1.27) for retinal vein occlusion, 0.89 (0.42 to 1.87) for retinal artery occlusion, and 0.87 (0.44 to 1.70) for optic neuritis.ConclusionsThis self-controlled case series showed no apparent increase in the risk of adverse ocular events after influenza vaccination among older adults. These results mitigate the concerns of older adults who may hesitate to receive influenza vaccination for fear of adverse ocular events.AbbreviationHR = hazard ratio; CI = confidence interval; RVO = retinal vein occlusion; SCCS = self-controlled case series
引用
收藏
页码:448 / 453
页数:6
相关论文
共 43 条
  • [1] Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden
    Bardage, Carola
    Persson, Ingemar
    Ortqvist, Ake
    Bergman, Ulf
    Ludvigsson, Jonas F.
    Granath, Fredrik
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343 : d5956
  • [2] Visual Snow-Like Symptoms and Posterior Uveitis followin COVID-19 Infection
    Braceros, Kathryn Kelani
    Asahi, Masumi G.
    Gallemore, Ron P.
    [J]. CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2021, 2021
  • [3] Centers for Disease Control Prevention, 2022, Flu vaccination coverage, United States, 202122 influenza season
  • [4] Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015-2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation
    Chon, Irina
    Saito, Reiko
    Hibino, Akinobu
    Yagami, Ren
    Dapat, Clyde
    Odagiri, Takashi
    Kondo, Hiroki
    Sato, Isamu
    Kimura, Shinji
    Kawashima, Takashi
    Kodo, Naoki
    Masaki, Hironori
    Asoh, Norichika
    Tsuchihashi, Yoshiko
    Zaraket, Hassan
    Shobugawa, Yugo
    [J]. VACCINE: X, 2019, 1
  • [5] Vaccine-Associated Uveitis
    Cunningham, Emmett T., Jr.
    Moorthy, Ramana S.
    Fraunfelder, Frederick W.
    Zierhut, Manfred
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (04) : 517 - 520
  • [6] Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
    Dhanasekaran, Vijaykrishna
    Sullivan, Sheena
    Edwards, Kimberly M.
    Xie, Ruopeng
    Khvorov, Arseniy
    Valkenburg, Sophie A.
    Cowling, Benjamin J.
    Barr, Ian G.
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] European Centre for Disease Prevention and Control (E.C.D.C.), Seasonal influenza vaccination and antiviral use in EU/EEA member state.
  • [8] Farrington P., 2018, Self-controlled case series studies: a modelling Guide with R.
  • [9] Vogt-Koyanagi-Harada Syndrome Associated With Bilateral Serous Macular Detachments Responsive to Immunomodulatory Therapy
    Gallagher, Micheal J.
    Yilmaz, Taygan
    Foster, Stephen
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING, 2009, 40 (03) : 345 - 347
  • [10] Grohskopf LA, 2022, MMWR-MORBID MORTAL W, V71, P1